Resume (Current Status- Dynamic)

CURRENT POSITIONS:

  • Clinical Associate Professor- University of Western Australia (Dept of Medicine) – February 2025 till date
  • Senior Lecturer, Curtin Medical School Western Australia – 2008 till date
  • Head of Department – Armadale Renal Services – Armadale Health Services WA June 2004 – till date
  • Renal Physician – Royal Perth Hospital and Health Services (Post reconfiguration of Health Services): Feb 2015 – till date
  • Renal Physician – St John of God Health Care (Murdoch): Jun 2004 till date
  • Renal Physician: Mount Hospital – June 2004 – till date.
  • Dobney Hypertension Centre, Medical Research Foundation, Royal Perth Hospital, Perth- Jan 2025 – till date
  • Linear Research Institute, Nedlands – 2019 till date

PAST POSITIONS:

  • Renal Physician – Peel Health Campus (Mandurah)- June 2004 till Dec 2023
  • Co –Clinical Lead, Renal Health Network, Health Networks Branch, Dept of Health, WA 2012 – till Jun 2020
  • Renal Physician – Fremantle Hospital and Health Services June 2004 – Jan 2015
  • Medical Advisor: VIFOR Pharmaceuticals (2013)
  • Medical Advisor: Afinitor and Tuberous Sclerosis (2014)
  • Medical / Research Advisor: Sinovent (2020)

GRANTS & AWARDS:

  • Feb 2014: Assoc Investigator for NHMRC Grant  for Feb 2014: APP1079502 Chronic Kidney Disease Centre of Research Excellence https://cre-ckd.centre.uq.edu.au/profile/95/hemant-kulkarni
  • June 2013: Kidney Health Australia: OPERATION ANGEL Award: For Inspirational Contribution to the patients with Kidney Care in Western Australia
  • 2012- 2013: ANZSN-Amgen Quality Assurance Grant ($ 10,000) for assessment of the development of Vascular access centre in Outer Metropolitan Hospital
  • 2007: ANZSN- NEPHROLOGY RESEARCH GRANT ($ 35,000) for clinical research in Iron Overload in Haemodialysis population
  • 1997: First Rank in University of Mumbai for DM (Nephrology) examination
  • Dec 1994: Pfizer Postgraduate Medical Award & Medallion & Scroll of honour for securing highest marks in Medicine in MBBS
  • 1990-1991: N F Surveyor Gold Medal for 1ts Rank in MBBS at Grant Medical College, University of Mumbai
  • March 1991: Prof M B Gharpure Memorial Prize (1st in Pharmacology) at Grant Medical College, University of Mumbai
  • Merit awards and Scholarships by Govt of India and Maharashtra: HSC certification

QUALIFICATIONS:

  • 2003: FRACP: Royal Australasian College of Physicians
  • 2002: AMC: Australasian Medical Council Examinations
  • 1999: MRCPCH (UK): Royal College of Physicians, United Kingdom
  • 1997: DM (NEPHROLOGY): Doctor of Medicine, University of Mumbai, India (!st rank in Univ of Mumbai)
  • 1995: MD (PEDIATRICS): Doctor of Medicine, University of Mumbai, India
  • 1994: DCH: College of Physicians and Surgeons, Mumbai, India
  • 1992: MBBS: Grant Medical College, University of Mumbai, India (1st rank in Grant Medical College)

MEMBERSHIPS:

  • Royal Australasian College of Physicians
  • Australian and New Zealand Society of Nephrology
  • Australian and New Zealand Society of Paediatric Nephrology
  • Indian Society of Nephrology (Life Member)
  • Indian Society of Organ Transplantation (Life Member)
  • AIMA – WA

PUBLICATIONS/ PRESENTATIONS

RESEARCH GATE: https://www.researchgate.net/profile/Hemant_Kulkarni2/publications

Public URL for Google Scholar http://scholar.google.com.au/citations?user=gRzjH2wAAAAJ

  • (2025): Audit of Safety of Metformin in Stage 5 CKD: Safety and Tolerability. Eimer McMullan, Siobhan Burke, Hemant Kulkarni. Presentation at Annual Meeting of ANZSN 2025
  • (2025) D Potter; A Conway, C Davies; S Kotwal, A Pilmore; S Menahem, Kulkarni, Hemant; M Roberts, B Mathew; P. Kolovos; S Thomas; C Dendle, G Irish, K Polkinghorne. Changes in dialysis practice patterns in Australia and New Zealand during the COVID-19 pandemic period: An ANZDATA observational cohort study. Accepted by NEPHROLOGY – July 2025
  • (2025) Light C, Heslop K, & Kulkarni H. (2025). Factors Affecting Seroconversion Rate Following Hepatitis B Vaccination in Patients with Stage 4 chronic kidney disease. Asian Journal of Research in Nephrology, 8(1), 91-104.
  • (2025) Vivien Wei-Anne Hsu, Nicole Swarbrick, Hemant Kulkarni, Andrew Redfern, Cynthia Hawks, Alarick Picardo, Steve P. McCombie, Dickon Hayne. Urothelial carcinoma in situ of the entire urinary tract with invasion into seminal vesicle: A case report. Urology Case Reports, 63 (2025) 103185.
  • 29 April 2025. Himanshu Pendse, Vincent Tiong, Greg Vanschie and Hemant Kulkarni. External Iliac Artery Dissection: An Under-Recognized Cause of Severe Post-Renal Transplant Hypertension Successfully Managed with Endovascular Stenting.. In process for publication – Int Journal of Translational Medicine (2025)
  • (Mini-oral 2025): Lijun Zhong, D Chan, Hemant Kulkarni, J Jamboti: Preserving Residual Kidney Function in Haemodialysis: Current Practices in Western Australia. Minioral Presentation, Renal Society of Australasia, 2025
  • (2025): Peter Kolovos, Christopher E Davies, Feruza Kholmurodova, Georgina Irish, Hemant Kulkarni, …., Solomon Menahem. Risk factors associated with 30‐day mortality following COVID‐19 infection in patients receiving kidney replacement therapy in Australia and New Zealand. Internal Medicine Journal Vol 55-4, 2025, Pages 622-629. http://dx.doi.org/10.1111/imj.16628
  • (2025): Harry Ashton, Hemant Kulkarni. Therapeutic drug monitoring and pharmacogenomic guided perhexiline therapy in kidney failure requiring haemodialysis: a case study. Journal of Pharmacy Practice and Research (2025) doi: 10.1002/jppr.70003

2024 and Prior: 

  • Light C, Heslop K, Kulkarni H. Comparison of Factors Affecting the Immune Response to Hepatitis B Vaccination in Patients with Stage 5 Chronic Kidney Disease-haemodialysis and Predialysis. Open Urol Nephrol J, 2024; 17: e1874303X304324. ttp://dx.doi.org/10.2174/011874303X304324240529133609
  • Updated results from the RUBY-3 study of Povetaciciept, an enhanced dual BAFF/APRIL antagonist in Autoantibody associated glomerulonephritis. Kidney International Reports, Vol 9 (4), S 505 (April 2024)
  • Povetaciciept, an enhanced dual BAFF/APRIL antagonist in Autoantibody associated glomerulonephritis. Kidney International Reports, Vol 9 (4), S-141 (April 2024)
  • Updated results from the RUBY-3 study of Povetaciciept, an enhanced dual BAFF/APRIL antagonist in Autoantibody associated glomerulonephritis. NDT (Neph Dial Transp Vol 39, Issue Supplement 1, 0431- (May 2024)
  • Prophylactic antibiotics before insertion of tunneled hemodialysis catheters: A Nationwide Cohort Study. Benjamin Lazarus et al on behalf of the REDUCCTION investigators – Submitted to JASN.
  • Younger adults were disproportionately affected by hemodialysis catheter infections in Australia: A Prospective Nationwide Cohort Study. Benjamin Lazarus et al on behalf of the REDUCCTION investigators – Submitted to JASN
  • Replacement Strategies for Tunnelled Hemodialysis Catheters with Complications: A Nationwide Cohort Study Benjamin Lazarus et al on behalf of the REDUCCTION investigators – Submitted to JASN
  • Casey Light, Karen Heslop, HEMANT KULKARNI: Hepatitis B vaccination in patients with stage 4/5 chronic kidney disease – a scoping review. Renal Society of Australasia Journal 2023; 19(1):68-76.
  • Smyth, B., Kotwal, S., Gallagher, M., Gray, N. A., & Polkinghorne, K. (2018). Dialysis catheter management practices in Australia and New Zealand. Nephrology (Carlton). 2018 Sep 28. . Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/30267459. doi:10.1111/nep.13507
  • Light C; Kulkarni H (Mar 2018). Booster hepatitis B vaccination in haemodialysis patients: Five-year prospective observational study Renal Society of Australasia Journal
  • Holman, R, Olynyk, JK, Kulkarni, H and Ferrari, P (2017), Characterisation of hepatic and cardiac iron deposition during standard treatment of anaemia in haemodialysis. Nephrology, Feb 2017, doi: 10.1111/nep.12735.
  • SD Roger, CA Gaillard, AH Bock, F Carrera…H Kulkarni (As Investigator Group)… et al. Safety of intravenous ferric carboxymaltose versus oral iron in patients with nondialysis-dependent CKD: an analysis of the 1-year FIND-CKD trial. Nephrology Dialysis Transplantation, 2016 doi: 10.1093/ndt/gfw26
  • Hoy, W. E., H. G. Healy, D. Waugh, M. D. Jose, H. Kulkarni, I. Katz, C. Nelson, K. Panaretto, and R. Walker. “Towards a national surveillance network for chronic kidney disease (CKD).” In Nephrology, vol. 19, pp. 58-88. 2014.
  • Casey Light, Hemant Kulkarni. TOLERABILITY AND SAFETY OF RAPID INTRAVENOUS PUSH BOLUS ADMINISTRATION OF IRON POLYMALTOSE 200MG OVER 15 MINUTES ON HAEMODIALYSIS: A PILOT STUDY. ANZSN Presentation . Nephrology Aug 2014
  • AL Graves, M Texler, L Manning, H Kulkarni. Successful treatment of renal allograft and bladder malakoplakia with minimisation of immunosuppression and prolonged antibiotic therapy. Nephrology, Vol 19, Suppl 1, 18-21, April 2014.
  • H Kulkarni, N Lenzo, A McLean‐Tooke. Causality of rhabdomyolysis and combined tetanus, diphtheria and acellular pertussis (Tdap) vaccine administration. The Journal of Clinical Pharmacology 53 (10), 1099-1102, 2013
  • Jo Ryan, Hemant Kulkarni, P Ferrari. SERUM GENTAMICIN MONITORING IS NOT WARRANTED WITH USE OF GENTAMICIN CITRATE LOCKS FOR HAEMODIALYSIS CENTRAL VENOUS CATHETER (CVC). ANZSN, Sept 2013
  • DW Johnson, FG Brown, M Clarke, N Boudville, TJ Elias, MWY Foo, B Jones, H Kulkarni.. Et al… The Effects of Biocompatible Compared with Standard Peritoneal Dialysis Solutions on Peritonitis Microbiology, Treatment, and Outcomes: the balANZ Trial  Peritoneal Dialysis International 32 (5), 497-506 ; 2012DW
  • Johnson, FG Brown, M Clarke, N Boudville, TJ Elias, MWY Foo, B Jones, H Kulkarni.. Et al… Effects of biocompatible versus standard fluid on peritoneal dialysis outcomes J Am Soc Nephrol 23, 1097-1107 , 2012
  • DW Johnson, FG Brown, M Clarke, N Boudville, TJ Elias, MWY Foo, B Jones, H Kulkarni.. Et al… The effect of low glucose degradation product, neutral pH versus standard peritoneal dialysis solutions on peritoneal membrane function: the balANZ trial. Nephrology Dialysis Transplantation. 2012
  • Ferrari P, Kulkarni H, Dheda S, Betti S, Harrison C, St. Pierre T, and Olynyk J. Serum Iron Markers Are Inadequate for Guiding Iron Repletion in Chronic Kidney Disease Clin J Am Soc Nephrol Jan 2011 (Published online on September 28, 2010 as doi:10.2215/CJN.04190510)
  • Clark BM, Boan P, Kulkarni H. A Case of Legionella longbeachae Pneumonia Complicated by Rhabdomyolysis and Acute Renal Failure Requiring Hemodialysis. Infectious Diseases in Clinical Practice. 18(6):413-416, November 2010.
  • JK Olynyk, P Ferrari, H Kulkarni, TC Tan, D Trinder. Non-invasive characterisation of significant hepatic iron overload in hyperferritinemic subjects HEPATOLOGY, Vol 48, Issue 4, 1170A, 2008
  • Singer R, Rhodes H, Chin G, Kulkarni H, Ferrari P. High prevalence of ascorbate deficiency in an Australian peritoneal dialysis population. Nephrology (Carlton), 2008: Volume 13 Issue 1 Page 17-22.
  • Howman H, Kulkarni H. Antibody-mediated acquired Pure Red Cell Aplasia after treatment with darbepoetin – Nephrology Dialysis Transplantation 2007 22(5):1462-1464.
  • Thomas MA, Luxton G, Moody HR, Woodroffe AJ, Kulkarni H, Lim W, Christiansen FT, Opelz G. Subjective and quantitative assessment of patient fitness for cadaveric kidney transplantation: the “equity penalty”. Transplantation. 2003 Apr 15;75(7):1026-9.
  • H Kulkarni, K Jureidini, P Trnka, P Henning, R Vigneswaran, S Harris
    Cystatin C is a promising marker of renal function in newborns during first 3 months. Nephrology Dialysis Transplantation 18 (18 (suppl 4): 808-813.), 808-813 2003
  • Playford D, Kulkarni H, Thomas M, Vivian J, Low A, Mander J, Perlman D, Finch P. Intra-ureteric capsaicin in loin pain haematuria syndrome: efficacy and complications. British Journal of Urology Int. 2002 Oct;90(6):518-21.
  • Kulkarni H, Goldwater PN, Martin A, Bettelheim KA. Escherichia coli ‘O’ group serological responses and clinical correlations in epidemic HUS patients. Comp Immunol Microbiol Infect Dis. 2002 Jul;25(4):249-68.
  • H Kulkarni, S Bichu, U Oza, A Kirpalani. Sulphonamide crystalluria induced acute renal failure in a renal allograft. —A case report,
    Indian Journal of Nephrology, Vol 7, No 1, 20-21, Jan-Mar 1997.
  • Patnekar PN, Kulkarni HA, Khopkar SR, Kulkarni VS, Nerurkar RS. Nevus flammeus in tuberous sclerosis Indian Pediatr. 1995 Sep;32(9):1038-9.
  • H KULKARNI: Antiphospholipid Syndrome in a single kidney- A case report: Indian Journal of Renal Sciences, 1999.
  • H KULKARNI: Can Cystatin C replace creatinine as a marker of renal function? Review article in Indian Journal of Renal Sciences, 1999.

CURRENT TRIALS:

(ACTIVE RECRUITMENT ON) A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Intravenously Administered PYC-003 in healthy volunteer and Type 1 ADPCKD

A Phase III, Randomised, Double -Blind, Active-controlled Study to Assess the Efficacy, Safety and Tolerability of Baxdrostat in Combination with Dapagliflozin Compared with Dapagliflozin Alone on Chronic Kidney Disease (CKD) Progression in Participants with CKD and High Blood Pressure. (BAXDUO ARTIC)

A Phase III, Randomised, Double-blind, Placebocontrolled, Event-driven Study to Assess the Efficacy, Safety and Tolerability of Baxdrostat in Combination
with Dapagliflozin Compared with Dapagliflozin Alone on Renal Outcomes and Cardiovascular Mortality in Participants with Chronic Kidney Disease and High
Blood Pressure. (BAX DUO PACIFIC)

(Soon commencing enrollment) A Phase II randomised, double-blind, parallel-group, multicentre, international trial to investigate the safety of vicadrostat and empagliflozin administered with simultaneous vs staggered initiation in SGLT2i-naïve participants with CKD with risk of kidney disease progression

Hepatitis B Vaccination in Advanced CKD – Stage 4 v/s Stage 5

Safety and tolerability of Metformin in Advanced CKD – GEKO Approved Study in progress

Safety and Tolerability of GLP1 analogues in Advanced CKD – GEKO Approved Study in Progress

The RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients with Severe CKD (MRI and Echo Substudy) https://classic.clinicaltrials.gov/ct2/show/NCT05374291

Zibotentan and Dapagliflozin for the Treatment of CKD (ZENITH-CKD Trial) (ZENITH-CKD) – https://classic.clinicaltrials.gov/ct2/show/NCT04724837

RUBY – 3 Trial – IgA (Closed for recruitment); SLE; Memb GN (Closed for recruitment), ANCA associated vasculitis:
Impressive results with auto antibody reduction
https://www.alpineimmunesciences.com/wp-content/uploads/2024/04/WCN-2024-RUBY-3-LB-poster_FINAL.pdf

ALXN1210-IgAN-320: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants with Immunoglobulin A Nephropathy (IgAN): IgA Nephropathy with proteinuria and biopsy

PHOSPHATE Study – Recruitment closed and followup extended for another 2 years (2026)

BEAT – CALCI TRIAL: Calciphylaxis on dialysis (Started – August 2024)